Interleukin-12 gene therapy prevents establishment of SCC VII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice

Laryngoscope

Volumn 108, Issue 2, 1998, Pages 261-268

  Myers, Jeffrey N ^a,b   Mank Seymour, Amy ^a   Zitvogel, Laurence ^a   Storkus, Walter ^a   Clarke, Martha ^a   Johnson, Candace S ^a   Tahara, Hideaki ^a   Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; MESSENGER RNA; VIRUS VECTOR;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; FEMALE; GENE TARGETING; GENE THERAPY; GENETIC TRANSFECTION; HEAD AND NECK CARCINOMA; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; VIRUS RECOMBINANT;

ANIMALS; CARCINOMA, SQUAMOUS CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; GENETIC VECTORS; HEAD AND NECK NEOPLASMS; IMMUNOTHERAPY; INTERLEUKIN-12; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; POLYMERASE CHAIN REACTION; RETROVIRIDAE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0031931280     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005537-199802000-00019     Document Type: Article

References (28)

1. Rice DH, Spiro RH. Current Concepts in Head and Neck Cancer. American Cancer Society; 1989.
2. Shah JP, Lydiatt W. Treatment of cancer of the head and neck. CA Cancer J Clin 1995;45:352-68.
3. Jacob HE. Current role of chemotherapy in the management of head and neck cancer. Adv Otolaryngol Head Neck Surg 1995;9:197-226.
4. Suen JY, Myers EN. Head and Neck Cancer, edn 1. New York: Churchill Livingstone; 1981.
5. Vitolo D, Letessier EM, Johnson JT, Whiteside TL. Immunologic effector cells in head and neck cancer. J Natl Cancer Inst Monogr 1992;13:203-8.
6. Whiteside TL, Betessier E, Hirabayashi H, et al. Evidence for local and systemic activation of immune cells by peritu-moral injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res 1993;53:5654-62.
7. Cortesina G, Sacchi M, Galeazzi E, De Stefani A. Immunology of head and neck cancer: perspectives. Head Neck 1993; 15:74-7.
8. Cortesina G, De Stefani A, Sacchi M, Rosso S, Galeazzi E. Immunomodulation therapy for squamous cell carcinoma of the head and neck. Head Neck 1993;15:266-70.
9. Mickel RA, Kessler DJ, Taylor JMG, Lichtenstein A. Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients. Cancer Res 1988;48:5017-22.
10. Wang MB, Lichtenstein A, Mickel RA. Hierarchical immuno-suppression of regional lymph nodes in patients with head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 1991;105:517-27.
11. Cortesina F, De Stefani A, Galeazzi E, et al. The effects of preoperative local interleukin-2 injections in patients with head and neck carcinoma: an immunological study. Acta Otolaryngol (Stockh) 1991;111:428-33.
12. Hadden JW, Endicott J, Baekey P, Skipper P, Hadden EM. Interleukins and contrasuppression induce immune regression of head and neck cancer. Arch Otolaryngol Head Neck Surg 1994;120:395-403.
13. Gately M, Wilson D, Wong H. Synergy between recombinant interleukin-2 and IL-2 depleted lymphokine-containing supernatants in facilitating allogenic human cytolytic T lymphocyte responses in vitro. J Immunol 1986;136: 1274-81.
14. Wong HL, Wilson DE, Jenson J, Familetti P, Stremlo D, Gately MK. Characterization of factor(s) which synergizes with recombinant interleukin-2 in promoting allogeneic human cytolytic T-lymphocyte responses in vitro. Cell Immunol 1987;111:39-54.
15. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF): a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827-45.
16. Gubler U, Chua AO, Schoenhaut DS, et al. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci U S A 1991;88:4143-7.
17. D'Andrea A, Rengaraju M, Waliante N, et al. Production of natural killer cell stimulatory factor (Interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992;176: 1378-98.
18. Aragane Y, Riemann H, Bhardwaj RS, et al. IL-12 is expressed and released by human keratinocytes and epidermoid carcinoma cell lines. J Immunol 1994;153:5366-72.
19. Trinchieri G. Interleukin-12 and its role in the generation of TH1 Cells. Immunol Today 1993;14:335-8.
20. Chan SH, Kobayshi M, Santoli D, Perussia B, Trinchieri G. Mechanisms of IFN-γ induction by natural killer cell stimulatory factor (NKSF/IL-12). J Immunol 1992;148:92-8.
21. Zeh HJ, Hurd S, Storkus WJ, Lotze MT. Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer. J Immunother 1993;14:155-61.
22. Nastala CL, Edington H, Storkus WJ, et al. Recombinant interleukin-12 administration induces tumor regression and high levels of interferon-gamma. J Immunol 1994;153: 1697-706.
23. Brunda MJ, Gately MK. Antitumor activity of interleukin-12. Clin Immunol Immunopathol 1994;71:253-5.
24. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of Interleukin-12 against murine tumors. J Exp Med 1993;178:1233-40.
25. Tahara H, Zeh HJ, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to murine melanoma in vivo. Cancer Res 1994;54:182-9.
26. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J Immunol 1995;155:1393-403.
27. O'Malley BW, Cope KA, Johnson CS, Schwartz MR. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 1997;123:20-4.
28. Fu, KK, Rayner PA, Lam KN. Modification of the effects of continuous low dose rate irradiation by concurrent chemotherapy infusion. Int J Radiat Oncol 1984;10: 1473-8.